Compounded semaglutide vs. Rybelsus: pill against pill

Semaglutide is a peptide, and the stomach breaks peptides down. Rybelsus works because each tablet is co-formulated with SNAC (salcaprozate sodium), which lets a small share of the dose cross the stomach lining. That is why its label insists on a routine: on waking, empty stomach, no more than 4 ounces of plain water, swallow whole, then nothing to eat, drink or take for 30 minutes.

In 2026 Novo Nordisk renamed the product. The original 3, 7 and 14 mg tablets are still labelled Rybelsus; a reformulated, smaller tablet in 1.5, 4 and 9 mg is sold as the Ozempic pill. A compounded oral semaglutide is something else again: a pharmacy-made tablet, sublingual or orally disintegrating preparation with its own excipients, strength and instructions. Temi's listed option, for example, is an orally disintegrating tablet with added pyridoxine (vitamin B6).

Nobody has compared a compounded oral semaglutide with Rybelsus, and for pills the absence matters more than it does for injections. The label shows why. Estimated absolute bioavailability is 0.4% to 1% for the 3, 7 and 14 mg Rybelsus tablets and 1% to 2% for the 1.5, 4 and 9 mg Ozempic tablets. Same molecule, same company, same enhancer, and the label still says the two are not substitutable milligram for milligram. Change the formulation and the dose that reaches the blood changes with it.

The outcome data sit with the manufactured tablets. The glycaemic trials summarised in the tablet label established the blood-sugar effect in type 2 diabetes, and the label now adds a cardiovascular indication for high-risk adults with diabetes. For weight, the relevant approved tablet is the Wegovy pill: in OASIS 4, oral semaglutide 25 mg daily produced a mean weight change of −13.6% against −2.2% on placebo over 64 weeks.

A compounded tablet has no label, so there is no reviewed figure for how much of its semaglutide is absorbed. Without that, a milligram on its packet cannot be translated into a Rybelsus-equivalent dose.

The tablet label lists nausea, abdominal pain, diarrhoea, decreased appetite, vomiting and constipation as reactions in at least 5% of people. Warnings match the injections: pancreatitis, gallbladder disease, kidney injury from dehydration, retinopathy complications, low blood sugar with insulin or sulfonylureas, and the boxed warning on thyroid C-cell tumours in rodents.

Two points are specific to pills. Oral semaglutide slows stomach emptying, so the label advises closer monitoring of other oral drugs with a narrow therapeutic window; in its own study, taking levothyroxine alongside the tablets raised total thyroxine exposure by 33%. And SNAC, the absorption enhancer, crossed the placenta in rat studies, while semaglutide's long washout is why the label says to stop at least two months before a planned pregnancy. A compounded tablet adds uncertainty rather than a known risk: if absorption differs from what your prescriber expects, side effects and results can both drift from one pack to the next.

For type 2 diabetes, Rybelsus or the Ozempic pill is the clear choice when you want a tablet. The dosing ladder is fixed (1.5 mg, then 4 mg, then 9 mg if needed, each step lasting at least 30 days), the cardiovascular indication is on the label, and Novo Nordisk lists the Ozempic pill at $149 to $299 a month self-pay depending on strength (Novo Nordisk press release, checked 28 Sep 2026).

For weight management, neither Rybelsus nor a compounded pill is the approved tablet; the Wegovy pill is, at $149 a month for 1.5 mg rising to $299 for 9 and 25 mg (NovoCare Pharmacy, checked 28 Sep 2026).

A compounded oral preparation fits someone who cannot use an injection and cannot reach either brand tablet. Go in knowing that its absorption is unmeasured, follow the pharmacy's instructions rather than Rybelsus's, and ask your prescriber whether a compounded injection, whose delivered dose is more predictable, would serve you better.